These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20524038)

  • 21. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Bose P; Simmons GL; Grant S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.
    Hirai H; Shimomura T; Kobayashi M; Eguchi T; Taniguchi E; Fukasawa K; Machida T; Oki H; Arai T; Ichikawa K; Hasako S; Haze K; Kodera T; Kawanishi N; Takahashi-Suziki I; Nakatsuru Y; Kotani H; Iwasawa Y
    Cell Cycle; 2010 Apr; 9(8):1590-600. PubMed ID: 20372067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of CDKs in RNA polymerase II transcription of the HIV-1 genome.
    Rice AP
    Transcription; 2019 Apr; 10(2):111-117. PubMed ID: 30375919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism.
    Corsino P; Horenstein N; Ostrov D; Rowe T; Law M; Barrett A; Aslanidi G; Cress WD; Law B
    J Biol Chem; 2009 Oct; 284(43):29945-55. PubMed ID: 19710018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinase pathways as targets for cancer treatment.
    Shapiro GI
    J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The peptidyl-prolyl isomerase Pin1 interacts with hSpt5 phosphorylated by Cdk9.
    Lavoie SB; Albert AL; Handa H; Vincent M; Bensaude O
    J Mol Biol; 2001 Sep; 312(4):675-85. PubMed ID: 11575923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9.
    Schmerwitz UK; Sass G; Khandoga AG; Joore J; Mayer BA; Berberich N; Totzke F; Krombach F; Tiegs G; Zahler S; Vollmar AM; Fürst R
    Arterioscler Thromb Vasc Biol; 2011 Feb; 31(2):280-8. PubMed ID: 21088252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.
    DePinto W; Chu XJ; Yin X; Smith M; Packman K; Goelzer P; Lovey A; Chen Y; Qian H; Hamid R; Xiang Q; Tovar C; Blain R; Nevins T; Higgins B; Luistro L; Kolinsky K; Felix B; Hussain S; Heimbrook D
    Mol Cancer Ther; 2006 Nov; 5(11):2644-58. PubMed ID: 17121911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter.
    Deng L; Ammosova T; Pumfery A; Kashanchi F; Nekhai S
    J Biol Chem; 2002 Sep; 277(37):33922-9. PubMed ID: 12114499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery.
    Fisher RP
    Transcription; 2019 Apr; 10(2):47-56. PubMed ID: 30488763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control.
    Wang X; Deng K; Wang C; Li Y; Wang T; Huang Z; Ma Y; Sun P; Shi Y; Yang S; Fan Y; Xiang R
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):414-423. PubMed ID: 31899991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
    Hu S; Marineau JJ; Rajagopal N; Hamman KB; Choi YJ; Schmidt DR; Ke N; Johannessen L; Bradley MJ; Orlando DA; Alnemy SR; Ren Y; Ciblat S; Winter DK; Kabro A; Sprott KT; Hodgson JG; Fritz CC; Carulli JP; di Tomaso E; Olson ER
    Cancer Res; 2019 Jul; 79(13):3479-3491. PubMed ID: 31064851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
    Reynisdóttir I; Polyak K; Iavarone A; Massagué J
    Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
    Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
    J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study.
    Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS
    ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Overview of CDK Enzyme Inhibitors in Cancer Therapy.
    Mounika P; Gurupadayya B; Kumar HY; Namitha B
    Curr Cancer Drug Targets; 2023; 23(8):603-619. PubMed ID: 36959160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II.
    Lu H; Yu D; Hansen AS; Ganguly S; Liu R; Heckert A; Darzacq X; Zhou Q
    Nature; 2018 Jun; 558(7709):318-323. PubMed ID: 29849146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin-dependent kinase-9 in B-cell malignancies: pathogenic role and therapeutic implications.
    Dominguez EC; Roleder C; Ball B; Danilov AV
    Leuk Lymphoma; 2023 Dec; 64(12):1893-1904. PubMed ID: 37552126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes.
    Salerno D; Hasham MG; Marshall R; Garriga J; Tsygankov AY; Graña X
    Gene; 2007 Dec; 405(1-2):65-78. PubMed ID: 17949927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
    Whittaker SR; Walton MI; Garrett MD; Workman P
    Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.